Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial-Reference-Cited by-同舟云学术

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial

Published:2013-02 Issue:2 Volume:165 Page:216-225
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Ambrosy Andrew P.,Vaduganathan Muthiah,Mentz Robert J.,Greene Stephen J.,Subačius Haris,Konstam Marvin A.,Maggioni Aldo P.,Swedberg Karl,Gheorghiade Mihai

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference21 articles.

1. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association;Roger;Circulation,2012

2. Heart disease and stroke statistics—2012 update: a report from the American Heart Association;Roger;Circulation,2012

3. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure;Gheorghiade;Heart Fail Rev,2012

4. Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period;Harinstein;Heart,2011

5. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure;Gheorghiade;JAMA,2006

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: Insights from a 6-month real-world study;International Journal of Cardiology;2024-12

2. Risk Factors for All-Cause Mortality in Patients Diagnosed with Advanced Heart Failure: A Scoping Review;Journal of Palliative Medicine;2024-07-31

3. Who Can Receive Clinical Benefit from Mid-Term Vericiguat Add-on Therapy Among Patients with Systolic Heart Failure Receiving Quadruple Medical Therapy?;International Heart Journal;2024-07-31

4. Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure;International Journal of Cardiology;2024-07

5. Implications of pulse wave velocity and central pulse pressure in heart failure with reduced ejection fraction;Blood Pressure;2024-05-31